Biotechnology stocks continued the blood shed on Monday. Shares across the sector tumbled several percentage points, along with exchange traded funds specializing in the industry. This constant downhill slide started last week and is raising questions among investors on whether the sector is finally running out of momentum, following news that U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
